2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Pathology, Bioinformatics, Profiling, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, APL, MDS, MPN, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

2663 Polypharmacy discussions in older adults with newly diagnosed acute myeloid leukemia (AML)

Jie Yin, MD, Marielle Jensen-Battaglia, PhD, DPT2, Amesha Narpaul, BS3, Yingzhu Chen, MS4, Soroush Mortaz-Hedjri, MD5, Erika Ramsdale, MD6, Mostafa Mohamed, MBBCh, PhD7, Jason Mendler, MD, PhD8, Jane Liesveld, MD9, Rachel Rodenbach, MD, MS10, Eric Huselton, MD11, Craig Maguire12, Bassil Botros, MD13, Azmeer Sharipol, PhD14, Ilana Massi15, Julie Moser, EdD16, Kah Poh (Melissa) Loh, MD, MS17
1 University of Rochester Medical Center, Rochester, New York, United States
2 University of Rochester Medical Center, Rochester, New York, United States
3 University of Rochester Medical Center, Rochester, New York, United States
4 University of Rochester Medical Center, Rochester, New York, United States
5 University of Rochester Medical Center, Rochester, New York, United States
6 University of Rochester Medical Center, Rochester, New York, United States
7 University of Rochester Medical Center, Rochester, New York, United States
8 University of Rochester Medical Center, Rochester, New York, United States
9 University of Rochester Medical Center, Rochester, New York, United States
10 University of Rochester Medical Center, Rochester, New York, United States
11 University of Rochester Medical Center, Rochester, New York, United States
12 University of Rochester Medical Center, Rochester, New York, United States
13 University of Rochester Medical Center, Rochester, New York, United States
14 University of Rochester Medical Center, Rochester, New York, United States
15 University of Rochester Medical Center, Rochester, New York, United States
16 University of Rochester Medical Center, Rochester, New York, United States
17 University of Rochester Medical Center, Rochester, New York, United States

Introduction

Polypharmacy, defined as the use of five or more medications, is highly prevalent among older adults with cancer. In older adults with acute myeloid leukemia (AML), polypharmacy is associated with worse survival. Little is known about how medication-related concerns are discussed during treatment decision-making encounters at the time of AML diagnosis. These visits represent a critical opportunity to identify potentially inappropriate medications, address patient concerns about medication burden, and integrate medication optimization into shared treatment decision-making. A better understanding of the extent, content, and management of polypharmacy-related discussions could inform interventions that improve medication management and support high-quality, patient-centered treatment decisions. In this study, we examined polypharmacy-related discussions during treatment decision-making visits of older adults with newly diagnosed AML.

Methods

This was a secondary analysis of a pilot randomized trial testing a geriatric assessment and value-based decisional intervention (UR-GOAL) aimed at improving shared decision-making. We recruited patients aged ≥60 years with AML and their oncologists. Patients were randomized to UR-GOAL or usual care. In the UR-GOAL arm, patients completed geriatric assessment, value clarification exercises, and assessment of prognostic understanding. Prior to treatment decision-making visits, oncologists and patients received a summary report of patient values, prognostic understanding, and geriatric assessment, including polypharmacy obtained from patient self-report of number of regularly used prescription medications. Clinical encounters were audio-recorded, transcribed, and independently coded by three investigators for polypharmacy-related concerns based on a codebook. Oncologist responses to concerns were categorized as addressed when an intervention was suggested, acknowledged when the concern was explored further without providing an intervention, or dismissed when the concern was not followed up. Group comparisons were performed using t-tests, Fisher's exact tests, or chi-square tests, as appropriate.

 

Results

We included 92 patients (46 UR-GOAL, 46 usual care) cared for by 8 oncologists.  Patients had a median age of 74 years (range 60-92), 63% were male, 94% were White, 62% were married, 47% had an Eastern Cooperative Group Performance Status of 1, 53% had adverse-risk AML, and 57% received lower-intensity treatment. A lower percentage of patients in the UR-GOAL arm had polypharmacy compared with usual care (39% vs. 52%, p=0.25). Overall, 71 polypharmacy concerns were identified, with similar numbers across study arms (36 in UR-GOAL and 35 in usual care); the mean number of concerns per transcript was 0.8.

 

Concerns were most commonly initiated by oncologists (56%), followed by caregivers (24%), and patients (20%). Most concerns were addressed (72%), followed by acknowledged (21%) and dismissed (7%). Concerns were more likely to be addressed in UR-GOAL than usual care (86% vs. 57%, p=0.01).

 

The most frequently discussed concerns were non-cancer drug-related side effects (24%), drug-drug interactions (21%), number of medications (14%), high-risk drugs per Beers criteria (13%), supportive medication (9%), and medication management (7%). The most common interventions were patient education and counseling (41%), non-cancer treatment modification (33%), interprofessional communication (16%), referral (2%), and caregiver discussion (2%). Management discussions were not different between arms.

 

When concerns were categorized by topics, they were commonly related to side effects of home prescription medications (26%), interaction of vitamins, minerals, herbs, cannabis, and probiotics with chemotherapy (16%), adjustment of home prescription medications (14%), and bleeding risk from antiplatelet or anticoagulation while on chemotherapy (12%).

 

Conclusions

In older adults with newly diagnosed AML, polypharmacy-related concerns during treatment decision-making visits were most commonly related to non-cancer medication side effects, drug interactions, and potentially inappropriate medications. Patients in the UR-GOAL arm were more likely to have their polypharmacy concerns addressed, suggesting that incorporation of medication assessment into decision-support interventions may promote more comprehensive discussion and management of medication-related issues.

Jie Yin, MD: No relevant conflicts of interest to declare.